Kamada Ltd Stock Price, News & Analysis

Kamada Ltd. reported fiscal year 2022 revenues of $129.3 million, a 25% increase from 2021, with EBITDA of $17.8 million, reflecting a 3x increase year-over-year. The fourth quarter alone saw revenues of $45.4 million, up 44% compared to the previous year. The company forecasts fiscal year 2023 revenues between $138 million and $146 million, representing anticipated growth. Key drivers include sales from CYTOGAM®, KEDRAB®, and GLASSIA® royalties. Kamada also achieved a record operating cash flow of $28.6 million in 2022, enhancing its cash position to $34.3 million.

Kamada Ltd. (NASDAQ: KMDA), a biopharmaceutical company focusing on rare diseases, will announce its financial results for Q4 and the full year ending December 31, 2022, on March 15, 2023, before U.S. market open. A conference call will be held the same day at 8:30 AM ET to discuss the results. Investors can participate by calling specific numbers or via a live webcast. Kamada's portfolio includes six FDA-approved plasma-derived products and a notable investigational product for AAT deficiency currently in a pivotal Phase 3 trial. The company aims to drive growth through its commercial strategies and R&D advancements.

Kamada Ltd. (NASDAQ: KMDA) announced it has submitted an application to the FDA to manufacture CYTOGAM® at its Israeli facility, expecting approval by mid-2023. This marks the completion of the technology transfer from CSL Behring. CYTOGAM is crucial for preventing cytomegalovirus disease post-transplantation and has the highest sales among Kamada's acquired IgG products, with gross margins exceeding 50%. The company plans to initiate commercial manufacturing in the second half of 2023, leveraging its operational capabilities for increased efficiency.

Kamada Ltd. (NASDAQ: KMDA) announced that its CFO, Chaime Orlev, will leave the company effective March 15, 2023, to pursue new opportunities. Orlev has been with Kamada since 2017 and played a crucial role in its transformation into a diversified biopharmaceutical company. As part of the transition, he will support the onboarding of his successor. Kamada specializes in specialty plasma-derived therapeutics and has a robust portfolio of FDA-approved products. It operates in over 30 countries and continues to advance its development pipeline, including ongoing clinical trials.

Kamada Ltd. (NASDAQ: KMDA) reported third-quarter 2022 revenues of $32.2 million, a 40% increase from the previous year, driven by the integration of its new FDA-approved IgG portfolio. Adjusted EBITDA reached $6.0 million, equating to a 19% margin. The company’s operating cash flow amounted to $5.5 million, elevating its cash position to $31.3 million as of September 30, 2022. Kamada reiterates its fiscal year 2022 revenue guidance of $125 million to $135 million, projecting a 20% to 30% increase over 2021.

Kamada Ltd. (NASDAQ: KMDA) is set to release its financial results for Q3 and the first nine months of 2022 on November 22, 2022, before U.S. markets open. Following the announcement, management will host a conference call at 8:30 AM ET to discuss the results. Investors can participate by phone or by joining a live webcast. Kamada specializes in plasma-derived therapeutics and has a diverse product portfolio including GLASSIA® and KEDRAB®. The company is focused on profitable growth and has a strong presence in the bio-pharmaceutical market.

Kamada Ltd. (NASDAQ: KMDA) announced progress in its pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy aimed at treating Alpha-1 Antitrypsin Deficiency (AATD). With 30 patients enrolled, the trial has proceeded without modification for the fourth time, according to the Data Safety Monitoring Board. Importantly, inclusion criteria were revised to enroll patients with severe airflow limitation, enhancing recruitment potential. The company plans to meet with the FDA and EMA in H1 2023 to discuss study progress and regulatory pathways.

Kamada Ltd. (NASDAQ: KMDA), a global biopharmaceutical company specializing in plasma-derived therapeutics, announced that Amir London, CEO, will present at the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 3:50 p.m. ET. Additionally, Mr. London will be available for virtual one-on-one investor meetings during the event. Interested investors should contact their Credit Suisse representative. The presentation will be accessible via a live webcast on Kamada's investor relations page, with a replay available for 30 days.

Kamada Ltd. (NASDAQ: KMDA) announced an extension of its supply tender with Canadian Blood Services for four specialty IgG products, securing about $7.5 million per year from 2023-2025, totaling approximately $22 million. The products, acquired in 2021, include CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF. The deal reinforces Kamada’s position in the Canadian market and follows a recent $11.4 million agreement for VARIZIG in Latin America. Manufacturing of CYTOGAM is set to begin in 2023 at Kamada's Israeli facility, pending regulatory approvals.